Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DPP IV Inhibitor Januvia First Out Of The Gate

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s type 2 diabetes treatment is approved a few weeks before the estimated user fee date of Novartis’ Galvus.
Advertisement

Related Content

Merck & Co. Executive Director Of Experimental Medicine Gary Herman: An Interview With “The Pink Sheet” DAILY
Januvia Gains Indication For Initial Diabetes Treatment With Metformin
Novartis To Resubmit Galvus In Mid-2009
Saxagliptin Plus Metformin Lowers HbA1C Levels Over Metformin Alone In Phase III Study
Merck Janumet Study Demonstrates Glucose Reductions In Two Measures
Merck’s Januvia/Metformin Combo To Be Branded Janumet
Merck Targeting Metabolic Disorders With Advinus Deal
OSI Seeks Partner For DPP-4 Inhibitor Paused At Phase III Gate
Alantos Joins DPP-4 Hunt With Help From France’s Servier
Merck’s Gardasil Records $70 Mil. In Sales In Q3

Topics

Advertisement
UsernamePublicRestriction

Register

PS063202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel